Redeye: Tessin - Muted risk appetite holding back sales
Redeye updates its estimates and valuation after reviewing Tessin's Q4 report, which showed weaker figures than expected. Despite the accelerated decline in sales during the quarter, we believe there is potential for a rapid rebound if institutional capital were to be secured.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/